VolitionRx announces share offering to boost product development and clinical studies

A portion of the funds raised may also be used for potential strategic acquisitions

VolitionRx -
Volition applies its Nucleosomics platform through its subsidiaries to develop simple, cost-effective blood tests for things like cancer diagnosis

VolitionRx Limited (NYSEAMERICAN:VNRX) announced a new funding round to support the epigenetics company’s continued product development and clinical studies.

The Austin-based company said that it is offering shares of the company in an underwritten public offering led by National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NASDAQ:NHLD).

All shares are being offered by Volition, with no firm details yet as to the offering’s size or terms, the company said Tuesday. A portion of the funds raised will also be used for potential strategic acquisitions.

READ: VolitionRx closes 1Q with $12M in cash while studying Nu.Q blood test as potential coronavirus diagnostic tool

Volition applies its Nucleosomics platform through its subsidiaries to develop simple, cost-effective blood tests to help diagnose a range of cancers and other diseases.

The firm recently shared preliminary results from a study on how its Nu.Q blood test can be used as a diagnostic or prognostic tool in the fight against the coronavirus (COVID-19).

The company said a recent proof of concept study involving 34 polymerase chain reaction (PCR) COVID-19 positive subjects and 50 control subjects revealed that nucleosomes were highly elevated in the PCR positive subjects.

Preliminary study results demonstrated an Area Under the Curve (AUC) for a single Nu.Q assay of 98.7% for PCR positive COVID versus control subjects with a sensitivity of 100% at 94% specificity.

A second Nu.Q assay also showed promising results with an AUC of 86.2%.

Volition said it plans to utilize the results of this trial and other ongoing studies to further its aim of developing a clinically useful product to help in the battle against the COVID-19 global pandemic and potentially other diseases.

Quick facts: VolitionRx


Price: 3.08 USD

Market Cap: $163.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


VolitionRx highlights strengthened balance sheet and strong progress on its...

VolitionRx (NYSEMKT:VNRX) Limited's Cameron (NYSE:CAM) Reynolds updates Proactive on the highlights of its second quarter. The company ended 2Q with a strong balance sheet with about $27.9 million in cash and cash equivalents. Reynolds says the period has seen them make significant progress on...

on 08/12/2021

2 min read